BOJI MEDICAL TECHNOLOGY CO.,LTD. Boji Medical Technology Co.,Ltd. Stock
Equities
300404
CNE100001Y00
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.07 CNY | -4.50% |
|
+4.40% | -9.83% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 957M 132M | Sales 2025 * | 1.23B 170M | Capitalization | 3.06B 424M |
|---|---|---|---|---|---|
| Net income 2024 * | 101M 13.98M | Net income 2025 * | 128M 17.72M | EV / Sales 2024 * | 3.2 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.49 x |
| P/E ratio 2024 * |
30.5
x | P/E ratio 2025 * |
24.5
x | Employees | 1,186 |
| Yield 2024 * |
0.37% | Yield 2025 * |
0.5% | Free-Float | 58.83% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.50% | ||
| 1 week | +4.40% | ||
| Current month | +4.40% | ||
| 1 month | +5.22% | ||
| 3 months | +37.24% | ||
| 6 months | -22.63% | ||
| Current year | -9.83% |
1 week
7.75
8.50
1 month
6.278.50
Current year
5.039.17
1 year
5.0312.88
3 years
5.0312.88
5 years
5.0314.43
10 years
3.5942.43
| Managers | Title | Age | Since |
|---|---|---|---|
Ting Cun Wang
CEO | Chief Executive Officer | 59 | 11-06-10 |
Xiu Qing Ou
DFI | Director of Finance/CFO | 42 | 03-11-30 |
Bo Tan
BRD | Director/Board Member | 42 | 05-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ting Cun Wang
CEO | Chief Executive Officer | 59 | 11-06-10 |
Yu Ping Han
PRN | Corporate Officer/Principal | 51 | 08-10-31 |
Quan Zhu
BRD | Director/Board Member | 52 | 08-01-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 8.07 | -4.50% | 15,717,000 |
| 24-05-09 | 8.45 | +4.32% | 22,105,660 |
| 24-05-08 | 8.1 | +0.37% | 17,831,290 |
| 24-05-07 | 8.07 | +0.88% | 12,886,490 |
End-of-day quote Shenzhen S.E., May 09, 2024
More quotes
Boji Medical Technology Co Ltd is a China-based company that provides Contract Research Organization (CRO) services. The Company mainly provides one-stop CRO services for the development and production of new drugs and medical devices for domestic and foreign pharmaceutical companies and other research institutions. The Company's CRO services include pre-clinical research services, clinical research services, other consulting services, pharmaceutical Contract Development Manufacture Organization (CDMO) services, pre-clinical independent research and development services, and technology achievement transformation services. The Company mainly conducts its businesses in the domestic market.
Calendar
2024-05-16
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
8.07
CNY
Average target price
11.74
CNY
Spread / Average Target
+45.48%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -9.83% | 424M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- 300404 Stock